基于数据挖掘探究王坤根教授治疗胃癌前病变用药规律

doi:10.20047/j.issn1673-7210.2023.05.35

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (932 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore professor Wang Kungen’s prescription rules for the treatment of gastric precancerous lesions, based on the traditional Chinese medicine inheritance assistant platform. Methods Cases diagnosed as gastric precancerous lesions through gastroscopic pathology reports were collected from professor Wang Kungen’s clinic in Zhejiang Provincial Hospital of Chinese Medicine from December 2016 to December 2020. Prescription database was established, and conclusions were drawn from frequency analysis, association rules, complex system entropy clustering analysis, and other processing methods through tradition Chinese medicine inheritance assistance platform. Results A total of 130 outpatient cases were obtained, and 130 first-diagnosed prescriptions were obtained, involving 132 kinds of Chinese medicines. Among them, 25 Chinese medicines with a frequency of ＞20 times were obtained, drugs to bitter cold, mainly return to the spleen, stomach, liver meridian. The core prescriptions were Chinese thorowax root, turmeric root tuber, pinellia tuber, dried tangerine peel, indian bread, dandelion, golden thread, and four new prescriptions were obtained from entropy clustering. Conclusion The core drugs of professor Wang Kungen’s treatment of gastric precancerous lesions are Chinese thorowax root, turmeric root tuber, pinellia tuber, dried tangerine peel, indian bread, dandelion, and golden thread. The main therapeutic principle is to soothe liver and clear heat, regulate qi and stomach, and remove dampness and phlegm.

Key words： Gastric precancerous lesions Wang Kungen Traditional Chinese medicine inheritance support platform Data mining

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CAI Lijun SHI Yihui HE Hui RUI Xiaowei MAO Xiangying FENG Tongfei WANG Kungen

Cite this article:

CAI Lijun SHI Yihui HE Hui RUI Xiaowei MAO Xiangying FENG Tongfei WANG Kungen. Explore the drug law of professor Wang Kungen in the treatment of gastric precancerous lesions based on data mining[J]. 中国医药导报, 2023, 20(5): 150-154.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.05.35 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I5/150

[1] 房静远，杜奕奇，刘文忠，等.中国慢性胃炎共识意见（2017年，上海）[J].中华消化杂志，2017，37（11）：721- 738.
[2] Akbari M，Tabrizi R，Kardeh S，et al. Gastric cancer in patients with gastric atrophy and intestinal metaplasia：A systematic review and meta-analysis [J]. PLoS One，2019，14（7）：e0219865.
[3] Mera RM，Bravo LE，Camargo MC，et al. Dynamics of Helicobacter pylori infection as a determinant of progression of gastric precancerous lesions：16-year follow-up of an eradication trial [J]. Gut，2018，67（7）：1239-1246.
[4] Eusebi LH，Telese A，Marasco G，et al. Gastric cancer prevention strategies：A global perspective [J]. J Gastroenterol Hepatol，2020，35（9）：1495-1502.
[5] 王淼蕾，刘俊宏，毛兰芳，等.胃癌前病变诊治中西医研究进展[J].中医药临床杂志，2020，32（1）：171-174.
[6] 梁依敏，梁文心，杨鑫龙，等.基于CiteSpace和VOSviewer的国内近30年来中医药治疗胃癌前病变研究的文献计量学分析[J].时珍国医国药，2022，33（3）：752-755.
[7] Xu W，Li B，Xu M，et al. Traditional Chinese medicine for precancerous lesions of gastric cancer：A review [J]. Biomed Pharmacother，2022，146：112542.
[8] Yang L，Li J，Hu Z，et al. A Systematic Review of the Mechanisms Underlying Treatment of Gastric Precancerous Lesions by Traditional Chinese Medicine [J]. Evid Based Complement Alternat Med，2020，2020：9154738.
[9] 唐仕欢，申丹，卢朋，等.中医传承辅助平台应用评述[J].中华中医药杂志，2015，30（2）：329-331.
[10] 南京中医药大学.中药大辞典[M].上海：上海科学技术出版社，2014：6.
[11] 涂华，胡运莲.基于网络药理学探讨左金丸治疗胃癌前病变机制[J].中国医药导报，2020，17（15）：155-158，172， 197.
[12] 孙洁，沈淑华，智屹慧，等.柴郁二陈汤治疗肝气犯胃诸证[J].山东中医药大学学报，2016，40（4）：338-340.
[13] 刘梅，郭小红，孙全，等.温郁金的化学成分和药理作用研究进展[J].现代药物与临床，2021，36（1）：204-208.
[14] Bao X，Zhang Y，Zhang H，et al. Molecular Mechanism of β-Sitosterol and its Derivatives in Tumor Progression [J]. Front Oncol，2022，12：926975.
[15] 王恒，于淼，李伟楠，等.半夏化学成分及抗肿瘤作用机制研究进展[J].中医药导报，2021，27（8）：49-52.
[16] 刘龙婵，王星宇，李林楠，等.青皮与陈皮化学成分及分析方法研究进展[J].中国中药杂志，2022，47（11）：2866- 2879.
[17] 邹继伟，胡海娥，李学莉，等.陈皮生物活性成分及其保健功能研究进展[J].饮料工业，2021，24（6）：68-72.
[18] 杜航，何文生，胡红兰，等.白术活性成分药理作用研究进展[J].江苏中医药，2022，54（5）：76-80.
[19] 聂文佳，徐帅师，张咏梅.蒲公英有效成分及其药理作用研究进展[J].辽宁中医药大学学报，2020，22（7）：140- 145.
[20] 王恩宇，王景辉，丁芮，等.“黄连-半夏”药对治疗胃癌的网络药理学研究和实验验证[J].中国中药杂志，2020， 45（8）：1779-1788.
[21] 周瑞，项昌培，张晶晶，等.黄连化学成分及小檗碱药理作用研究进展[J].中国中药杂志，2020，45（19）：4561- 4573.
[22] 高炜，徐艳霞，刘圆圆，等.小檗碱调控核因子κB信号转导通路对幽门螺杆菌感染人胃癌细胞的影响[J].世界中医药，2022，17（12）：1708-1711，1718.
[23] 丁伟.四气五味与脾胃[J].河南中医，2019，39（2）：176- 179.
[24] 阮祥美，余莹，胡玲.“半枝莲-白花蛇舌草”药对治疗胃癌的网络药理学作用机制分析[J].中华中医药学刊，2020，38（11）：176-180，289.
[25] 许晶，石凤芹，杜可心，等.基于网络药理学探讨“半枝莲-白花蛇舌草”抗乳腺癌的作用机制[J].中国中药杂志，2020，45（18）：4448-4454.